|
|||
2009-12-04 20:10:00 CET 2009-12-04 20:11:53 CET REGULATED INFORMATION Biotie Therapies - Company AnnouncementDirected issue of new shares in Biotie Therapies Corp. to institutional investorsBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 4 DECEMBER 2009 at 9.10 p.m. Directed issue of new shares in Biotie Therapies Corp. to institutional investors Not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or South Africa. The Board of Directors of Biotie Therapies Corp. ("Biotie" or"Company") has decided to offer a maximum of 14,432,000 new shares in Biotie through a directed share issue against cash payment. The subscription price is EUR 0.50 per share. The new shares will be offered in deviation from the shareholders' pre-emptive subscription right to a limited number of institutional investors in Finland and internationally (the "Offering"). Biotie has engaged Nomura Code Securities Limited to act as the lead manager in connection with the Offering. The Offering is made in order to strengthen Biotie's working capital, to provide further financing for the Company's R&D programs and to extend the Company's shareholder base. The subscription period will end on 7 December 2009 at 11 a.m. (Finnish time). In the event of oversubscription, the Offering may be completed prematurely. The subscription price of EUR 0.50 per share was determined by the Board of Directors on the basis of the current price of Biotie's share in the trading on the NASDAQ OMX Helsinki stock exchange, and based on the recommendation by the lead manager. The new shares are offered based on the authorisation by the Extraordinary General Meeting of Shareholders of Biotie held on 29 October 2009. The new shares will amount to approximately 9.99 per cent of the total number of shares and votes in Biotie before the Offering, and approximately 9.1 per cent of the total number of shares and votes in Biotie after the Offering provided that the Offering is subscribed in full. The subscription price of the new shares will be registered in its entirety to the share capital of Biotie. In Turku, 4 December 2009 Biotie Therapies Corp. The Board of Directors For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com www.biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media DISCLAIMER: The information herein may not be distributed or sent into the United States, Australia, Canada, Japan or South Africa. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. The information contained herein does not constitute an offer of securities for sale in the United States. The securities referenced in this release may not be offered or sold in the United States absent registration or an exemption from registration as provided in the United States Securities Act of 1933, as amended, and the rules and regulations thereunder. Biotie Therapies Corporation does not intend to register any portion of the placement in the United States or to conduct a public offering of any securities in the United States. This communication does not constitute an offer of securities to the public in the United Kingdom. This communication is directed only at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FP Order") and (iii) high net worth entities falling within Article 49(2) of the FP Order, and other persons to whom it may lawfully be communicated, (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to, and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Nomura Code Securities Limited ("Nomura") is acting exclusively for Biotie Therapies Corporation and no one else in connection with the placing. It will not regard any other person (whether or not a recipient of this release) as its respective and will not be responsible to anyone other than Biotie Therapies Corp for providing the protections afforded to its clients, nor for giving advice in relation to the placing or any transaction or arrangement referred to herein. No representation or warranty, express or implied, is made by Nomura as to the accuracy, completeness or verification of the information set forth in this release. |
|||
|